VRDN - Company ID 0001590750
The table below shows Viridian Therapeutics, Inc.DE's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$276.39M | -$232.32M | -$184.17M | -$93.84M | -$54.58M | -$29.78M |
| Capital expenditure | $495.00K | $511.00K | $898.00K | $797.00K | $338.00K | $42.00K |
| Investing cash flow | -$37.56M | -$228.65M | -$94.25M | -$115.13M | -$74.29M | -$50.48M |
| Dividends paid | - | - | - |
Viridian Therapeutics, Inc.DE reported operating cash flow of -$276.39M for fiscal year 2025. That is down 19.0% from -$232.32M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$14.76M (FY 2016) to -$276.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $426.74M | $457.74M | $225.67M | $322.24M | $125.28M | $101.31M |